Genlantis, a division of Gene Therapy Systems, Inc., is focused on developing kits for HIV and HBV diagnostics, genetic transfection, gene expression, gene silencing, RNA interference, primary cell culture, lab sterilization equipment, and sample preparation in proteomics research. Services include cloning, plasmid design, tagging, and production techniques or options. The company is focused on the development of protein expression tools within proteomics as well as efficient delivery technologies for both in vitro and in vivo applications. The patented Tap Express® and Xi-Clone Instant Enzymeless PCR Cloning technologies are available for licensing. These patented technologies offer scientists the ability to design experiments involving hundreds or even thousands of proteins simultaneously.
